PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26222F0634Emergency krystexxa — Horizon Therapeutics Usa, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 15, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Horizon Therapeutics Usa, Inc

Recipient

Oct 15, 2022

PoP end

$232K

Obligated

$232K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Horizon Therapeutics Usa, Inc — $90

Contract facts

Federal

Contract number36C26222F0634

Also listed as36C262-22-F-0634

Also listed as36F79719D0224-36C26222F0634

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentHorizon Therapeutics Usa, Inc

CAGE6TDL9

UEISK1UK7S74GB3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0224

Place of performanceLA VERGNE TN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

Related solicitation600-22-4-119-3289

PoP startSep 16, 2022

PoP end (current)Oct 15, 2022

Obligated$232K

Current value$232K

Potential value$232K

EMERGENCY KRYSTEXXA is a federal award for 262-Network Contract Office 22 (36C262) held by Horizon Therapeutics Usa, Inc. Estimated value $232K ($232K obligated). Current period of performance ends Oct 15, 2022. Last award drew 1 bidder. Place of performance: LA VERGNE TN. Related solicitation 600-22-4-119-3289.

Recompete timing

Public

● Past PoP end (1406 days ago)

Current PoP ended Oct 15, 2022 (1406 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26222F0634?

36C26222F0634 (Emergency krystexxa) is a 262-Network Contract Office 22 (36C262) award with a potential value of $232K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-22-F-0634?

36C262-22-F-0634 is the dashed form of PIID 36C26222F0634 (Emergency krystexxa), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26222F0634?

262-Network Contract Office 22 (36C262) awarded 36C26222F0634 to Horizon Therapeutics Usa, Inc (potential $232K).

Who is the incumbent on 36C26222F0634?

Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Oct 15, 2022.

When does Horizon Therapeutics Usa, Inc’s 36C26222F0634 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 15, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 16, 2022 · refreshed monthly